QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.075259v1 312/1/53    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gardiner, S. M. Articles by Bennett, T. Search for Related Content PubMed PubMed Citation Articles by Gardiner, S. M. Articles by Bennett, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB INDOMETHACIN LOSARTAN POTASSIUM

CARDIOVASCULAR

Regional Hemodynamic Actions of Selective Corticotropin-Releasing Factor Type 2 Receptor Ligands in Conscious Rats

Centre for Integrated Systems Biology and Medicine School of Biomedical Sciences, University of Nottingham, Nottingham, United Kingdom (S.M.G., J.E.M., P.A.K., T.B.); and Clinical Pharmacology Unit, University of Cambridge, Centre for Clinical Investigation, Addenbrooke's Hospital, Cambridge, United Kingdom (A.P.D., K.E.W.)

In conscious male Sprague-Dawley rats, we compared regional hemodynamic actions of the selective corticotropin-releasing factor type 2 (CRF₂) receptor ligands human and mouse urocortin 2 (hUCN2 and mUCN2, respectively) with those of CRF. Bolus i.v. doses of 3 and 30 pmol kg^-1 hUCN2, mUCN2, or CRF had no significant hemodynamic actions, but at doses of 300 and 3000 pmol kg^-1, all three peptides caused dose-dependent tachycardia and hypotension, with rapid-onset, short-duration, mesenteric vasodilatation and slower-onset, more prolonged hindquarters vasodilatation but little or no change in renal vascular conductance. Pretreatment with the nonselective CRF receptor antagonist astressin or the selective CRF₂ receptor antagonist antisauvagine 30 abolished all the cardiovascular actions of all three peptides. Indomethacin had no effect on responses to hUCN2, and there was no evidence for any involvement of nitric oxide (NO) in the vasodilator actions of hUCN2. There was no evidence that recruitment of angiotensin- and endothelin-mediated vasoconstrictor mechanisms counteracted the vascular actions of hUCN2. The results indicate that the hemodynamic effects of i.v. hUCN2, mUCN2, and CRF depend on activation of CRF₂ receptors and do not involve NO or prostanoids.

Address correspondence to: Professor S. M. Gardiner, School of Biomedical Sciences, University of Nottingham NG7 2UH. UK. E-mail: sheila.gardiner{at}nottingham.ac.uk

This article has been cited by other articles:

				S. M. Gardiner, J. E. March, P. A. Kemp, and T. Bennett A Comparison between the Cardiovascular Actions of Urocortin 1 and Urocortin 2 (Stresscopin-Related Peptide) in Conscious Rats J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 221 - 226. [Abstract] [Full Text] [PDF]

				M. E. Davis, C. J. Pemberton, T. G. Yandle, S. F. Fisher, J. G. Lainchbury, C. M. Frampton, M. T. Rademaker, and A. M. Richards Urocortin 2 Infusion in Healthy Humans: Hemodynamic, Neurohormonal, and Renal Responses J. Am. Coll. Cardiol., January 30, 2007; 49(4): 461 - 471. [Abstract] [Full Text] [PDF]